Posted in

Synchron Halts Brain Implant Trials Following Defects

Close up of brain implant hardware

Synchron Halts Brain Implant Trials Following Defects

Synchron has announced a voluntary pause in its clinical trials, marking a difficult phase for its next-generation brain implant development. The company, which is based in Brooklyn, identified that the cable assembly connecting the device to its internal electronics was failing to meet performance expectations in early human trials.

This suspension follows a period of rapid expansion for the firm. As part of a larger corporate restructuring, the company is shifting its focus toward a new team in San Diego, aiming to rectify the issues found in the brain implant hardware. This transition involves moving production in-house to gain tighter control over the design of the lead cables.

Brain Implant: The Challenge of Wireless Neural Interfaces

Synchron’s Stentrode technology is distinct because it avoids the need for invasive brain surgery. Instead, it uses a catheter to place a mesh-like brain implant into the jugular vein. While the first-generation device successfully allowed users to send texts and control consumer electronics like the Apple Vision Pro, the second-generation model aims to remove external wires entirely.

The move to wireless Bluetooth connectivity has introduced new technical complexities. Although the company insists that no safety issues have occurred with the current brain implant installations, the performance of the data transfer cable was deemed insufficient for the high-fidelity requirements of the clinical study.

How This Compares to Existing Flagship Hardware

Compared to other industry players that often require more invasive craniotomy procedures, Synchron’s approach remains a leading candidate for non-surgical neural interfaces. Yet, the current pause underscores the volatility of the industry. The company is currently upgrading the entire brain implant system rather than just replacing the cables, a move that suggests a need for deeper integration between the electrode mesh and the wireless transmitter.

  • Strategic Shift: Consolidating operations in San Diego.
  • Hardware Focus: Bringing lead manufacturing in-house.
  • Market Position: Minimally invasive alternative to traditional interfaces.
  • Trial Status: Enrollment paused at US, Australian, and Canadian sites.

The Bottom Line: The pause in enrollment is a measured response to a technical hurdle. Synchron has reaffirmed its commitment to the participants already using the device, ensuring their long-term care remains a priority. By addressing these hardware flaws now, the company hopes to secure the reliability needed for the next phase of its brain implant clinical trials, ensuring that the final product is both safe and highly performant for end-users.

For full official background and direct documentation, read the source coverage on wired Reporting.

Hardware Architecture, Gaming Tech, and Future Mobility Columnist evaluating semiconductors and EVs.

3 thoughts on “Synchron Halts Brain Implant Trials Following Defects”

Leave a Reply

Your email address will not be published. Required fields are marked *